Terrance P. Coyne - 06 Aug 2025 Form 4 Insider Report for Royalty Pharma plc (RPRX)

Role
EVP & CFO
Signature
/s/ Sean Weisberg, as Attorney-in-Fact for Terrance P. Coyne
Issuer symbol
RPRX
Transactions as of
06 Aug 2025
Transactions value $
$0
Form type
4
Filing time
08 Aug 2025, 16:58:17 UTC
Previous filing
20 May 2025
Next filing
07 Nov 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Coyne Terrance P. EVP & CFO C/O ROYALTY PHARMA PLC, 110 EAST 59TH STREET, NEW YORK /s/ Sean Weisberg, as Attorney-in-Fact for Terrance P. Coyne 08 Aug 2025 0001814876

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction RPRX Class A Ordinary Shares Award $0 +3.7K +7.6% $0.00 52.3K 06 Aug 2025 TPC RP EPA1 LLC F1
holding RPRX Class A Ordinary Shares 790K 06 Aug 2025 By TPC RP 2021, LLC
holding RPRX Class A Ordinary Shares 23.3K 06 Aug 2025 By IRA
holding RPRX Class A Ordinary Shares 1.5K 06 Aug 2025 Direct
holding RPRX Class A Ordinary Shares 24.2K 06 Aug 2025 By Spouse's IRA
holding RPRX Class A Ordinary Shares 1.45K 06 Aug 2025 By Spouse

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction RPRX LP interests in RPI US Partners 2019, LP Gift $0 -1K -2.25% $0.00 43.4K 08 Aug 2025 Class A Ordinary Shares 10K By TPC ICAI, LLC F2, F3
holding RPRX LP interests in RPI US Partners 2019, LP 484K 06 Aug 2025 Class A Ordinary Shares 4.84M $0.00 By TPC RP, LLC F3
holding RPRX LP interests in RPI US Partners 2019, LP 118K 06 Aug 2025 Class A Ordinary Shares 1.18M $0.00 By TPC RP 2021, LLC F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Reflects the exempt acquisition by the Reporting Person pursuant to Rule 16b-3 of Class A Ordinary Shares of the Issuer in connection with the settlement of Equity Performance Awards.
F2 No limited partnership interests in RPI US Partners 2019, LP ("RPI US LP") are being exchanged by the Reporting Person. Each limited partnership interest in RPI US LP ("RPI US LP Interest") may be exchanged for ten Class B Interests in Royalty Pharma Holdings Limited ("Holdings"). Each Class B Interest in Holdings so distributed will be exchanged for one Class A Ordinary Share of the Issuer. Any exchanges will be made pursuant to the terms of the Amended and Restated Exchange Agreement. No additional value will be paid by the Reporting Person in connection with an exchange.
F3 Represents RPI US LP Interests. Each RPI US LP Interest can be exchanged for ten Class B Interests in Holdings at any time and for no additional value, which exchange right does not expire until so converted. Upon such exchange, each Class B Interest in Holdings issued in exchange for a RPI US LP Interest will be exchanged for one Class A Ordinary Share of the Issuer for no additional value.